Statin-related adverse events a nocebo effect?
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phaseLiterature - Gupta A, Thompson D, Whitehouse A, et al. - The Lancet 2017, Epub ahead of print
- In total, 60 612 distinct AEs occurred.
- In the blinded randomized phase, definite or probably muscle-related AEOIs were reported in 298 statin- and 283 placebo-treated patients (HR 1.03, 95% CI 0.88-1.21, P=0.72), erectile dysfunction in 272 statin- and 302 placebo-treated patients (HR 0.88, 95% CI 0.75-1.04, P=0.13) and sleep disturbance in 149 statin- and 210 placebo-treated patients (HR 0.69, 95% CI 0.56-0.85, P=0.0005). As too few cases of cognitive impairment were reported, analyses were not statistically reliable regarding this AE (31 vs 32, HR 0.94, 95% CI 0.57-1.54, P=0.81).
- Findings were similar in sensitivity analyses based on only definite AEOIs or when more possible AEOIs were included.
- Regarding other AEs, renal and urinary disorders occurred more among patients on atorvastatin (HR 1.23, 95% CI 1.08-1.41, P=0.002).
- In the non-blinded non-randomized phase, overall less AEOIs were reported compared to the blinded phase. However, muscle-related AEOIs were reported more often in statin users than non-users (HR 1.41, 95% CI 1.10-1.79, P=0.006), which proportional excess was similar between atorvastatin- or placebo-assigned patients of blinded phase (P interaction=0.63).
- There was no significance difference of other prespecified AEs between statin-users and non-statin-users in non-blinded phase (erectile dysfunction HR 0.89, 95% CI 0.66-1.20, P=0.44, sleep disturbance HR 0.87, 95% CI 0.63-1.20, P=0.40, cognitive impairment HR 0.59, 95% CI 0.34-1.02, P=0.06). Findings were similar in sensitivity analyses.
- When non-blinded comparisons were adjusted for baseline age, sex, race, smoking, diabetes, left ventricular hypertrophy, total cholesterol and systolic blood pressure, HRs were minimally affected. For muscle-related AEs, HR changed to 1.43 (95% CI 1.12-1.83).
- Regarding other AEs in unblinded phase, only musculoskeletal and connective tissue disorders (HR 1.17, 95%C CI 1.06-1.29, P=0.001) and blood and lymphatic system disorders (HR 1.40, 95% CI 1.04-1.88, P=0.03) occurred more often among statin users.
In the blinded randomized phase of the ASCOT-LLA trial, the number of muscle-related AEs were comparable between statin-treated and placebo-treated patients. However, these AEs were significantly more often reported when these same patients knew that they were taking a statin during the extended non-blinded non-randomized phase. This observation is consistent with a nocebo effect, whereby subjective AEs are probably a result of a treatment thought that causes some particular side-effects. These data suggest that muscle-related AEOIs are not causally related to statin-use and therefore, the benefits of statins in reducing cardiovascular events should override concerns about reports of side-effects.